• Cue Biopharma delivered an EPS of -$0.09, exceeding estimates of -$0.13 with a positive surprise of 30.77%.
• Q2 revenue reached approximately $2.95 million, surpassing the expected $2 million, showcasing a 47.70% surprise.
• The company secured a strategic partnership with Boehringer Ingelheim, which includes an upfront payment of $12 million and potential milestone payments of about $345 million.

Cue Biopharma Inc. CUE specializes in developing novel therapies for autoimmune diseases and cancer. The latest quarterly report highlighted a positive trend in financial performance.

Meanwhile, the partnership with Boehringer Ingelheim enhances its financial position, providing necessary resources to expand its drug pipeline.